Combinations of an anti-HER2-drug and pertuzumab antibody conjugate

摘要

A therapeutic combination for use in a method for the treatment of a cancer expressing ErbB2, wherein the method comprises administering to a mammal a therapeutic combination as a combined formulation or alternatively, wherein the therapeutic combination comprises a therapeutically effective amount. of trastuzumab-MCC-DM1 and a therapeutically effective amount of pertuzumab, where administration of the therapeutic combination results in a synergistic effect.